Search peptides, terms, sources/
Immune and longevity

Epithalon

Also known as: Epitalon · Epithalone · AEDG peptide

Synthetic four-amino-acid peptide studied in ageing research. Not licensed in the UK; evidence is mostly laboratory and animal work from one group.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

5 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Epithalon is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials2 human trials · 2 human observational · 1 animal · 1 lab (in-vitro)

What is Epithalon?

Epithalon is a synthetic four-amino-acid peptide modelled on a pineal gland extract, studied in longevity and ageing research. It is not licensed in the UK, and the evidence is mostly laboratory and animal work, plus small human studies, largely from a single research group.

Also spelled Epitalon, its sequence is Ala-Glu-Asp-Gly, modelled on the pineal extract epithalamin. The research covers telomere biology and age-related hormone function, and comes almost entirely from one Russian research group, with little independent replication.

Class
Synthetic pineal/neuroendocrine bioregulator peptide
Origin
Fully synthetic
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Epithalon work?

How epithalon works is not settled. Cell and animal studies suggest antioxidant effects, changes in melatonin production and more activity of telomerase, an enzyme that protects chromosome ends. Most of this comes from one research group, and the review authors say the mechanism is not yet confirmed.

The mechanism in more detail

A 2025 peer-reviewed narrative review notes that despite more than 25 years of research, the precise mechanisms of action of Epithalon remain unconfirmed. Several mechanisms have been proposed and variously evidenced in preclinical and in-vitro work, but none has been established as the sole or primary pathway.

Studies suggest antioxidant activity, reflected in reduced lipid peroxidation and free-radical markers in animal tissue, and modulation of melatonin synthesis via changes in pineal AANAT and pCREB expression. In cultured human cell lines, Epithalon has been shown, using the TRAP protocol, to increase telomerase activity and extend replicative lifespan beyond untreated controls; this remains in-vitro data from a single research programme and has not been independently replicated by an outside laboratory. Direct DNA-binding at specific sequence motifs has also been proposed as a possible epigenetic-regulation pathway, alongside modulation of inflammatory signalling markers such as IL-2 mRNA expression and STAT1 phosphorylation.

These proposed mechanisms are supported mainly by in-vitro and animal data rather than confirmed human mechanistic studies, and the review’s own authors caution that mechanistic confirmation is incomplete. Reporting on Epithalon’s proposed mechanisms should not be read as evidence that the peptide is effective for, or recommended for, any anti-ageing or longevity purpose.

Mechanisms and targets

AntioxidantEpigenetic/DNA-binding modulation (proposed)Melatonin/circadian regulationTelomerase modulationDNA sequence motifs (proposed epigenetic target)Pineal AANAT/pCREB signalling pathwayTelomerase enzyme complex

Classification and structure

Names
Epithalon; Epitalon; Epithalone; AEDG peptide; TP-4 (Russian-language literature). Not to be confused with Epithalamin; the original bovine pineal-gland polypeptide extract from which the synthetic tetrapeptide Epithalon was modelled; these are related but distinct substances
Class
Synthetic pineal/neuroendocrine bioregulator peptide
Origin
Fully synthetic
Structure
Ala-Glu-Asp-Gly (AEDG), a four-amino-acid synthetic peptide. Molecular dynamics work describes two internal salt bridges and one intramolecular hydrogen bond that constrain its conformational freedom; commercially available as the free-base, acetate salt, or trifluoroacetate (TFA) salt.
Routes used in the research
Routes varied across the literature: subcutaneous, intraperitoneal and intramuscular injection in most animal studies; peri-ocular injection in the human retinitis pigmentosa study; sublingual administration in the human circadian-rhythm study; intranasal and oral administration in some rat studies; and direct application in cell culture. No single route is standard, which limits comparison across studies. This is not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Epithalon has 6 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

6 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
15000

Cell-culture telomerase activity Preliminary

Epitalon exposure elongated telomeres and increased telomerase activity (TRAP protocol) in telomerase-positive HeLa cultures and human fetal lung fibroblasts, extending replicative lifespan beyond untreated controls in culture.

Study type
Lab (in-vitro)
Population
Human fetal lung fibroblast line (602/17), HeLa cells (Khavinson et al., cited in the review)
Source
1 Araj et al., 2025

Limitation: Originates from a single research group; no replication by an independent laboratory identified.

Limitations in full

Originates from a single research group; no replication by an independent laboratory identified. Described here from a review of the work, not the original paper.

Ex-vivo elderly donor lymphocytes Limited

Ex-vivo human lymphocytes from elderly donors (75-88 years) showed telomere elongation averaging around 33% after Epitalon exposure, but with materially inconsistent individual responses (some samples showed statistically significant increases, others significant decreases).

Study type
Human observational
Population
PHA-stimulated peripheral blood lymphocytes, elderly vs. younger donors
Source
1 Araj et al., 2025

Limitation: Internally inconsistent results explicitly reported ("variable individual responses"); single research group; ex-vivo cell assay, not an in-vivo human outcome.

Retinitis pigmentosa human trial Limited

A non-blinded human trial using parabulbar injection reported visual-function improvement (visual acuity, visual-field expansion, scotoma reduction) in patients with retinitis pigmentosa, versus a conventional-treatment comparator group, with no side effects reported by the treated patients.

Study type
Human trial
Population
162 patients, ages 18-72, retinitis pigmentosa
Source
1 Araj et al., 2025

Limitation: Non-blinded, active-comparator (not placebo) design; single research group.

Limitations in full

Non-blinded, active-comparator (not placebo) design; single research group. Described here from a review, not the original publication.

Sublingual melatonin and clock genes Limited

A sublingual-administration study in 75 women reported increased melatonin production (via urinary 6-sulfatoxymelatonin) and altered circadian clock-gene expression versus placebo over 20 days.

Study type
Human trial
Population
75 women, sublingual, 20 days, placebo-controlled
Source
1 Araj et al., 2025

Limitation: Randomisation and blinding are not stated in the review that describes it.

Limitations in full

Randomisation and blinding are not stated in the review that describes it. Single study, single group.

Russian 12-year mortality programme Limited

A long-running, non-blinded Russian clinical/observational programme in elderly patients reported roughly 28% lower all-cause mortality and roughly two-fold lower cardiovascular mortality in treated versus untreated groups over 12 years.

Study type
Human observational
Population
Elderly patient cohorts, Russia (Korkushko et al. 2006; related Khavinson 2003 programme data)
Source
2 Korkushko et al., 2006

Limitation: Non-blinded, non-randomised programme design, not a controlled trial; single research consortium; no independent Western replication identified.

Limitations in full

Non-blinded, non-randomised programme design, not a controlled trial; single research consortium; no independent Western replication identified. This is the single most consequential human claim associated with this peptide and it rests on the weakest study design among those cited here.

Multi-species preclinical literature Limited

Extensive multi-species preclinical work (mice, rats, Drosophila, non-human primates) reports antioxidant effects, reduced tumour incidence/multiplicity in cancer-prone mouse strains, lifespan extension, and normalisation of age-related endocrine/metabolic parameters (melatonin/cortisol rhythm, glucose tolerance) with Epitalon administration.

Study type
Animal
Population
Multiple species/strains (CBA mice, HER-2/neu transgenic mice, Wistar/Sprague-Dawley rats, rhesus monkeys, Drosophila)
Source
1 Araj et al., 2025

Limitation: Large volume and consistent direction of effect across many individual studies, but concentrated almost entirely within one research consortium's output; no replication outside that group has been identified; no controlled human data corresponding to these specific endpoints (tumour incidence, lifespan) exists.

What safety findings have been reported?

3 safety findings are recorded for Epithalon. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Animal genotoxicity and nephrotoxicity

No genotoxic effects were reported in Drosophila lifespan studies; Epitalon was reported as "not nephrotoxic" in rat models; no interaction with mu- or delta-opioid receptors was found.

Source
1 Araj et al., 2025

No adverse events reported

No reported adverse events among treated patients in the retinitis pigmentosa human trial.

Source
1 Araj et al., 2025

Authors state toxicity data missing

The review's own authors state explicitly that "additional studies on short- and long-term toxicity" are essential and describe current safety data as having "critical issues... missing."

Source
1 Araj et al., 2025

What is Epithalon's UK regulatory status?

Marketing authorisation
None. No MHRA marketing authorisation exists for any Epithalon/Epitalon product. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for epithalon or epitalon.
Prescription status
Not applicable; no licensed UK product exists to classify.
Medicine class
Would meet the Human Medicines Regulations 2012 (SI 2012/1916), Regulation 2 definition of a "medicinal product" if administered or marketed with a view to a pharmacological or physiological effect in humans, an unlicensed medicinal product in that context, on the same basis as the other unlicensed research peptides in this catalogue.
MHRA position
Unlicensed medicinal product if supplied or marketed for human administration with a therapeutic or anti-ageing purpose, under the general prohibition in the Human Medicines Regulations 2012.
Authorised use
None.
Other restrictions
None identified beyond the standard unlicensed-medicine enforcement framework. Whether epithalon or epithalamin holds licensed-medicine status in Russia has not been established from a primary regulatory source.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Epithalon is recorded as not licensed in the UK (checked 14 November 2026).

References

3 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L (2025). Overview of Epitalon - Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 26(6):2691DOI 10.3390/ijms26062691 · PMID 40141333 · Original ↗
  2. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA (2006). Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bulletin of Experimental Biology and Medicine, 142(3):356-359DOI 10.1007/s10517-006-0365-z · PMID 17426848 · Original ↗
  3. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Epithalon

What is Epithalon?

Epithalon is a synthetic four-amino-acid peptide modelled on a pineal gland extract, studied in longevity and ageing research. It is not licensed in the UK, and the evidence is mostly laboratory and animal work, plus small human studies, largely from a single research group. Read what it is.

Is Epithalon licensed in the UK?

PeptGuru records Epithalon's UK status as: Not licensed in the UK. None. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Epithalon show?

PeptGuru records 6 research findings for Epithalon: 2 from human trials, 2 from human observational studies, 1 from an animal study and 1 from a lab (in-vitro) study. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Epithalon?

3 safety findings are recorded, including: animal genotoxicity and nephrotoxicity; no adverse events reported; authors state toxicity data missing. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Epithalon?

All 3 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Regulatory update · UK status now cites a dated MHRA database check.

How findings are graded: the grading method. All changes.

  • MOTS-cMitochondrial open reading…

    16-amino-acid peptide encoded in mitochondrial DNA, studied in mice and cells. Not licensed in the UK. No published trial gave MOTS-c to people; human studies measured the body's own levels.

    Immune and longevityHuman trialsEvidence reviewed
    PreliminaryNot licensed in the UK
  • GHK-CuCopper peptide GHK

    Copper-binding tripeptide studied for skin ageing and wound healing. Topical cosmetic use; no licensed injectable product in the UK.

    Repair and regenerationHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • SermorelinSermorelin acetate

    Synthetic growth-hormone-releasing hormone fragment studied in children with growth hormone deficiency. Not licensed in the UK; evidence is mainly from before 2000.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • Elamipretide

    Synthetic four-amino-acid peptide studied in rare mitochondrial diseases. US accelerated approval for Barth syndrome; not authorised in the UK. A large phase 3 trial failed.

    Immune and longevityHuman trialsEvidence reviewed
    PreliminaryNot licensed in the UK

Compare Epithalon with MOTS-c

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.